miR-130b and miR-128a are essential lineage-specific codrivers of t(4;11) MLL-AF4 acute leukemia.

Blood
Camille MaloufKatrin Ottersbach

Abstract

t(4;11) MLL-AF4 acute leukemia is one of the most aggressive malignancies in the infant and pediatric population, yet we have little information on the molecular mechanisms responsible for disease progression. This impairs the development of therapeutic regimens that can address the aggressive phenotype and lineage plasticity of MLL-AF4-driven leukemogenesis. This study highlights novel mechanisms of disease development by focusing on 2 microRNAs (miRNAs) upregulated in leukemic blasts from primary patient samples: miR-130b and miR-128a. We show that miR-130b and miR-128a are downstream targets of MLL-AF4 and can individually drive the transition from a pre-leukemic stage to an acute leukemia in an entirely murine Mll-AF4 in vivo model. They are also required to maintain the disease phenotype. Interestingly, miR-130b overexpression led to a mixed/B-cell precursor (BCP)/myeloid leukemia, propagated by the lymphoid-primed multipotent progenitor (LMPP) population, whereas miR-128a overexpression resulted in a pro-B acute lymphoblastic leukemia (ALL), maintained by a highly expanded Il7r+c-Kit+ blast population. Molecular and phenotypic changes induced by these two miRNAs fully recapitulate the human disease, including central nerv...Continue Reading

References

Feb 12, 1998·Proceedings of the National Academy of Sciences of the United States of America·K B GaleM F Greaves
Feb 15, 2005·Early Human Development·Mel Greaves
Apr 5, 2005·Nature Genetics·Azra KrekNikolaus Rajewsky
Dec 7, 2007·Proceedings of the National Academy of Sciences of the United States of America·Shuangli MiJianjun Chen
Nov 4, 2008·Cancer Cell·Andrei V KrivtsovScott A Armstrong
Jan 17, 2009·Leukemia·S Yendamuri, G A Calin
May 3, 2011·Current Genomics·Leigh-Ann Macfarlane, Paul R Murphy
Apr 13, 2012·The New England Journal of Medicine·Martin SchrappeMartin Zimmermann
Nov 13, 2012·Cell Stem Cell·Eric R LechmanLuigi Naldini
Dec 12, 2012·EMBO Molecular Medicine·James Scott McClellan, Ravindra Majeti
Oct 1, 2011·Therapeutic Advances in Hematology·Stephen S ChungChristopher Y Park
Feb 4, 2014·CA: a Cancer Journal for Clinicians·Elizabeth WardAhmedin Jemal
Dec 4, 2014·Cancer Cell·Aniruddha J DeshpandeScott A Armstrong
Mar 3, 2015·Nature Genetics·Anna K AnderssonUNKNOWN St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project
Aug 13, 2015·ELife·Vikram AgarwalDavid P Bartel
Aug 25, 2015·Nature Immunology·Malay MandalMarcus R Clark
May 18, 2016·Nucleic Acids Research·Sasha BabickiDavid S Wishart
Sep 17, 2016·Haematologica·Shinsuke HirabayashiUNKNOWN Tokyo Children’s Cancer Study Group (TCCSG)
Nov 20, 2016·Experimental Hematology·Laura GodfreyThomas A Milne
Aug 19, 2017·Cellular and Molecular Life Sciences : CMLS·Camille Malouf, Katrin Ottersbach
Jun 28, 2019·Nature Communications·Laura GodfreyThomas A Milne

❮ Previous
Next ❯

Citations

Oct 30, 2021·Disease Models & Mechanisms·Alasdair DuguidKatrin Ottersbach
Nov 26, 2021·Blood·Juerg Schwaller

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.